Phenominer Database Results (13 results)

 
 
Table "column sort" updates the order of the bars in the chart.
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Record ID Study ID
LEW.1F percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 10 100.0 % in vivo visual assessment 0.0 0 69677 1159
LEW.1N percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 54.0 % in vivo visual assessment 0.0 0 69678 1159
BBDR/Rhw percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait female 66 days-126 days 13 100.0 % in vivo visual assessment 0.0 0 69922 1241
E3/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) (for 120 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 25 0.0 % in vivo visual assessment 1.0368E7 0 69966 1160
LEW/Han percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 11 82.0 % in vivo visual assessment 0.0 0 69676 1159
DA/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) (for 120 days) Vingsbo-Lundberg C, et al., Nat Genet 1998 Dec;20(4):401-4 joint integrity trait both 0 days 30 87.0 % in vivo visual assessment 1.0368E7 0 69595 1160
BBDR/Rhw percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait male 66 days-126 days 11 100.0 % in vivo visual assessment 0.0 0 69921 1241
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait female 66 days-126 days 7 0.0 % in vivo visual assessment 0.0 0 69924 1241
E3/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 23 0.0 % in vivo visual assessment 0.0 0 69680 1159
DA/ZtmRhd percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 17 100.0 % in vivo visual assessment 0.0 0 69679 1159
BN/SsN percentage of study population developing chronic experimental arthritis during a period of time Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 joint integrity trait male 66 days-126 days 13 0.0 % in vivo visual assessment 0.0 0 69923 1241
DXE2/Ztm percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 24 30.0 % in vivo visual assessment 0.0 0 69682 1159
DXE3/Ztm percentage of study population developing chronic experimental arthritis during a period of time pristane (150 ul) Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 joint integrity trait both 56 days-98 days 20 0.0 % in vivo visual assessment 0.0 0 69683 1159